Clinical Trial Update: Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children [Phase 3]

View source ↗

Summary

Phase 3 trial assessing bilastine ophthalmic solution in children for allergic conjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• bilastine ophthalmic solution 0.6% (bilastine)

Snippet

Sponsor: Faes Farma, S.A. | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED